Mammaglobin as a Marker for Breast Cancer Detection

乳房珠蛋白作为乳腺癌检测的标志物

• 批准号: 6678159
• 负责人: TIMOTHY Peter FLEMING
• 金额: $ 15.3万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-02 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6678159
• 关键词: biomarker; breast neoplasms; clinical research; data collection methodology /evaluation; enzyme linked immunosorbent assay; gene expression; human subject; immunocytochemistry; neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer invasiveness; neoplasm /cancer relapse /recurrence; oncoproteins; polymerase chain reaction; protein quantitation /detection; serology /serodiagnosis; statistics /biometry; women's health

DESCRIPTION (provided by applicant): Mammaglobin is a breast-specific gene that has shown promise as a new marker for the specific detection of breast cancer. There are several important features that make mammaglobin an ideal candidate as a marker for breast cancer detection. One, it is a breast-specific gene, therefore mammaglobin's detection outside the breast indicates breast cancer disease. Secondly, the high percentage of primary breast cancers that are mammaglobin positive (more than 80%), and an equally high percentage expression pattern in metastatic breast cancer, make mammaglobin a promising candidate marker gene for breast cancer detection. Thirdly, mammaglobin is a secreted protein of low molecular weight, and preliminary data indicate its presence in the sera of some breast cancer patients. Therefore, mammaglobin may have utility as a serum marker for breast cancer detection. The immediate goals of this study will be to: 1) Using the ELISA assay for the serum detection of mammaglobin, we will evaluate and establish mammaglobin levels in normal women. This aim will help establish baseline values in both pre- and postmenopausal women, pregnant women, and explore factors that may modify mammaglobin levels. 2) Using the ELISA assay, we will evaluate the levels of mammaglobin in breast cancer patients and correlate this data to the primary tumor using immunohistochemical examination for mammaglobin. The presence of circulating breast tumor cells will be examined using a specific RT/PCR analysis of buffy coats from these samples. 3) Test the hypothesis that mammaglobin expression in blood by ELISA and/or RT-PCR will predict response to therapy and predict relapse in patients with mammaglobin expressing breast tumors. The scope of this proposal is to address whether mammaglobin protein can be detected in the serum of women with breast cancer and determine if serum detection of mammaglobin has any correlation to breast cancer when compared to normal control groups.

描述（申请人提供）：乳腺珠蛋白是一种乳腺特异性基因，有望成为乳腺癌特异性检测的新标志物。有几个重要的特征使乳房珠蛋白成为乳腺癌检测标记物的理想候选者。第一，它是一种乳腺特异性基因，因此在乳房外检测到乳房珠蛋白表明乳腺癌疾病。其次，乳腺珠蛋白阳性的原发性乳腺癌的高百分比（超过80%），以及转移性乳腺癌中同样高的百分比表达模式，使乳腺珠蛋白成为乳腺癌检测的有希望的候选标记基因。第三，乳房珠蛋白是一种低分子量的分泌蛋白，初步数据表明它存在于一些乳腺癌患者的血清中。因此，乳房珠蛋白可能可用作乳腺癌检测的血清标志物。本研究的近期目标是： 1)使用ELISA法检测血清中的乳房珠蛋白，我们将评估和建立正常妇女的乳房珠蛋白水平。这一目标将有助于建立绝经前和绝经后妇女、孕妇的基线值，并探索可能改变乳腺珠蛋白水平的因素。 2)使用ELISA检测，我们将评估乳腺癌患者的乳房珠蛋白水平，并使用免疫组化检测乳房珠蛋白将此数据与原发肿瘤相关联。将使用来自这些样本的血沉棕黄层的特异性RT/PCR分析来检查循环乳腺肿瘤细胞的存在。 3)通过ELISA和/或RT-PCR检测血液中的乳房珠蛋白表达，以预测乳房珠蛋白表达乳腺肿瘤患者对治疗的反应和复发。 本提案的范围是解决是否可以在乳腺癌女性血清中检测到乳房珠蛋白，并确定与正常对照组相比，乳房珠蛋白的血清检测是否与乳腺癌相关。